McGill Scientists Boost Natural Killer Cells to Penetrate and Destroy Hard-to-Treat Tumors

Discover how McGill University scientists are using small-molecule drugs and NK cells to penetrate tumor barriers and provide safer, faster cancer immunotherapy.

By: AXL Media

Published: Apr 25, 2026, 9:49 AM EDT

Source: Information for this report was sourced from EurekAlert

Revolutionizing Immune Response Against Aggressive Solid Tumors

A research team at McGill University’s Rosalind & Morris Goodman Cancer Institute has pioneered a method to dismantle the biological barriers that protect tumors from the immune system. By focusing on natural killer cells, which serve as the body's primary defense against malignancy, scientists have found a way to bypass the protective shielding that often allows tumors to grow unchecked. This development is aimed specifically at hard-to-treat cancers that have traditionally resisted conventional treatments, providing a potential lifeline for patients with limited remaining clinical options.

Molecular Protein Suppression Unlocks Enhanced Cellular Killing Power

The core of the discovery involves the inhibition of two specific proteins, PTPN1 and PTPN2, which usually limit the intensity of the immune response. According to the study, suppressing these proteins allows natural killer cells to overcome the suppressive environment created by tumors, effectively turning them into more aggressive hunters. In preclinical trials, this technique proved successful in destroying human cancer cells across a diverse range of pathologies, including kidney cancer, glioblastoma, and triple-negative breast cancer, while also slowing tumor expansion in animal subjects.

Transitioning from Permanent Genetic Editing to Temporary Chemical Boosting

One of the most significant shifts in this new methodology is the move away from permanent genetic modification. While many modern immunotherapies rely on gene editing to alter immune cells, such changes are permanent and carry a risk of long-term, uncontrollable side effects. The McGill team instead utilized small-molecule drugs to induce a reversible boost in cell activity. This strategy offers a safer profile, as the enhanced state of the cells is temporary and can be more easily managed by clinicians during the course of treatment.